

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
SCHEDULE 13D

Under the Securities Exchange Act of 1934  
(Amendment No. 4)\*

**Intellia Therapeutics, Inc.**

(Name of Issuer)

**COMMON STOCK, PAR VALUE \$0.0001 PER SHARE**

(Title of Class of Securities)

**45826J105**

(CUSIP Number)

**Scott A. Brown**  
**General Counsel and**  
**Chief Administrative Officer**  
**Novartis Institutes for BioMedical Research, Inc.**  
**250 Massachusetts Avenue**  
**Cambridge, MA 02139**  
**(617) 871-8000**

**With a copy to:**

**G. Scott Lesmes, Esq.**  
**Hillary P. Daniels, Esq.**  
**Morrison & Foerster LLP**  
**2000 Pennsylvania Avenue NW, Suite 6000**  
**Washington, D.C. 20006**  
**(202) 887-1500**

(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

**August 6, 2020**

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see the Notes*).

1.	Names of Reporting Persons Novartis Institutes for BioMedical Research, Inc.
<hr/>	
2.	Check the Appropriate Box if a Member of a Group (See Instructions)
(a)	<input type="radio"/>
(b)	<input type="radio"/>
<hr/>	
3.	SEC Use Only
<hr/>	
4.	Source of Funds (See Instructions) WC
<hr/>	
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) <input type="radio"/>
<hr/>	
6.	Citizenship or Place of Organization Delaware
<hr/>	
Number of Shares Beneficially Owned by Each Reporting Person With	7. Sole Voting Power None
	8. Shared Voting Power 4,352,295
	9. Sole Dispositive Power None
	10. Shared Dispositive Power 4,352,295
<hr/>	
11.	Aggregate Amount Beneficially Owned by Each Reporting Person 4,352,295
<hr/>	
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="radio"/>
<hr/>	
13.	Percent of Class Represented by Amount in Row (11) 7.4%*
<hr/>	
14.	Type of Reporting Person (See Instructions) CO
<hr/>	

\* This calculation is based on 58,740,613 shares of common stock, par value \$0.0001 per share ("Common Stock"), outstanding as of July 31, 2020, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020, filed by the Issuer with the Securities and Exchange Commission ("SEC") on August 6, 2020.

1. Names of Reporting Persons

Novartis AG

---

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

---

3. SEC Use Only

---

4. Source of Funds (See Instructions)

AF

---

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

---

6. Citizenship or Place of Organization

Switzerland

---

7. Sole Voting Power

None

---

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

8. Shared Voting Power

4,352,295

---

9. Sole Dispositive Power

None

---

10. Shared Dispositive Power

4,352,295

---

11. Aggregate Amount Beneficially Owned by Each Reporting Person

4,352,295

---

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

---

13. Percent of Class Represented by Amount in Row (11)

7.4%\*

---

14. Type of Reporting Person (See Instructions)

CO, HC

---



---

\* This calculation is based on 58,740,613 shares of Common Stock outstanding as of July 31, 2020, as reported by the Issuer on its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020, filed by the Issuer with the SEC on August 6, 2020.

## Explanatory Note

This Amendment No. 4 (the “Amendment No. 4”) amends the statement on Schedule 13D originally filed by the Reporting Persons on May 11, 2016 and amended on December 14, 2017, March 23, 2018 and March 30, 2020 (the “Schedule 13D”). The Items below amend the information disclosed under the corresponding Items of the Schedule 13D as described below. Except as specifically provided herein, this Amendment No. 4 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not defined herein shall have the meanings attributed to them in the Schedule 13D.

### Item 1. Security and Issuer

Item 1 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:

“This Statement on Schedule 13D relates to the common stock, par value \$0.0001 per share (the “Common Stock”) of Intellia Therapeutics, Inc., a Delaware corporation (the “Issuer”). The Issuer’s principal executive offices are located at 40 Erie Street, Cambridge, Massachusetts 02139.”

### Item 2. Identity and Background

Item 2 of the Schedule 13D is hereby amended such that all references to Schedule I contained within Item 2 and otherwise within the Schedule 13D shall refer to the Schedule I included in this Amendment No. 4.

Item 2(c) of the Schedule 13D is hereby amended and restated in its entirety to read as follows:

“(c) NIBRI is a company organized under the laws of the State of Delaware and is a wholly-owned indirect subsidiary of Novartis. NIBRI is a research organization that works to discover innovative medicines that treat disease and improve human health.

Novartis is a corporation organized under the laws of Switzerland and is the publicly owned parent of a multinational group of companies specializing in the research, development, manufacturing and marketing of healthcare products, led by innovative pharmaceuticals and also including high-quality generic pharmaceuticals. Novartis is the 100% indirect owner of NIBRI.”

### Item 5. Interest in Securities of the Issuer

Items 5(a) and (b) of the Schedule 13D are hereby amended and restated in their entirety to read as follows:

“(a)-(b) As of the date hereof, each of the Reporting Persons may be deemed, for purposes of Rule 13d-3 of the Act, directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of 4,352,295 shares of Common Stock. Each Reporting Person has shared voting and dispositive power with the other Reporting Person.

Based on the 58,740,613 shares of Common Stock outstanding as of July 31, 2020, as reported by the Issuer on its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020, filed by the Issuer with the SEC on August 6, 2020, the Common Stock held by the Reporting Persons constitutes 7.4% of the outstanding shares of Common Stock of the Issuer.

NIBRI is a wholly-owned indirect subsidiary of Novartis. Novartis, as the parent company of NIBRI, may be deemed to beneficially own all of the shares of Common Stock held directly by NIBRI.”

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Pursuant to Rule 13d-1(k)(1)(iii) of Regulation 13D-G of the General Rules and Regulations of the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached statement is filed on behalf of each of them.

Dated: August 20, 2020

**NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.**

By: /s/ Scott A. Brown

Name: Scott A. Brown

Title: Authorized Signatory

**NOVARTIS AG**

By: /s/ Christian Rehm

Name: Christian Rehm

Title: Authorized Signatory

By: /s/ Felix Eichhorn

Name: Felix Eichhorn

Title: Authorized Signatory

**DIRECTORS AND EXECUTIVE OFFICERS OF  
NOVARTIS AG AND NOVARTIS INSTITUTES FOR BIOMEDICAL  
RESEARCH, INC.**

DIRECTORS AND EXECUTIVE OFFICERS OF NOVARTIS AG

The name, function, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis AG are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite an individual's name refers to employment with Novartis AG and (ii) the business address of each director and executive officer of Novartis AG is Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland.

Name	Relationship to Novartis AG	Present Principal Occupation	Citizenship
Joerg Reinhardt, Ph.D.	Chairman of the Board of Directors	Chairman of the Board of Directors	German
Enrico Vanni, Ph.D.	Vice Chairman of the Board of Directors	Independent Director	Swiss
Nancy C. Andrews, M.D., Ph.D.	Director	Dean emerita, vice chancellor emerita for academic affairs, Duke University School of Medicine, US; Nanaline H. Duke Professor of Pediatrics, pharmacology and cancer biology, Duke University, US	American/Swiss
Ton Buechner	Director	Independent Director	Dutch/Swiss
Patrice Bula	Director	Executive vice president and head of strategic business units, marketing, sales, and Nespresso, Nestle SA, Switzerland	Swiss
Srikant Datar, Ph.D.	Director	Arthur Lowes Dickinson Professor, Harvard Business School, US; Faculty Chair of the Harvard Innovation Lab, US; Senior Associate Dean for University Affairs, Harvard Business School, US	American

Elizabeth (Liz) Doherty	Director	Independent Director	British
Ann Fudge	Director	Independent Director	American
Bridgette Heller	Director	Co-founder and Chief Executive Officer, Shirley Proctor Puller Foundation, US	American
Frans van Houten	Director	Chief Executive Officer and chairman of the executive committee and the board of management, Royal Philips NV, Netherlands	Dutch
Simon Moroney	Director	Independent Director	German/New Zealander
Andreas von Planta, Ph.D.	Director	Senior Counsel, Lenz & Staehelin, Switzerland	Swiss
Charles L. Sawyers, M.D.	Director	Chair of the Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, US; Professor of Medicine and of Cell and Developmental Biology, Weill Cornell Graduate School of Medical Sciences, US	American
William T. Winters	Director	Chief Executive Officer and director of Standard Chartered PLC, UK	British, American

---

Vasant (Vas) Narasimhan, M.D.	Member of the Executive Committee; Chief Executive Officer	Member of the Executive Committee; Chief Executive Officer	American
Steven Baert	Member of the Executive Committee; Chief People and Organization Officer	Member of the Executive Committee; Chief People and Organization Officer	Belgian
Bertrand Bodson	Member of the Executive Committee; Chief Digital Officer	Member of the Executive Committee; Chief Digital Officer	Belgian
James (Jay) Bradner, M.D.	Member of the Executive Committee; President, Novartis Institutes for BioMedical Research	Member of the Executive Committee; President, Novartis Institutes for BioMedical Research	American
Harry Kirsch	Member of the Executive Committee; Chief Financial Officer	Member of the Executive Committee; Chief Financial Officer	German/Swiss
Shannon Thyme Klinger	Member of the Executive Committee; Chief Legal Officer	Member of the Executive Committee; Chief Legal Officer	American
Steffen Lang, Ph.D.	Member of the Executive Committee; Global Head of Novartis Technical Operations	Member of the Executive Committee; Global Head of Novartis Technical Operations	German/Swiss
Klaus Moosmayer, Ph.D.	Member of the Executive Committee; Chief Ethics, Risk and Compliance Officer	Member of the Executive Committee; Chief Ethics, Risk and Compliance Officer	German
Richard Saynor	Member of the Executive Committee; Chief Executive Officer, Sandoz	Member of the Executive Committee; Chief Executive Officer, Sandoz	British
Susanne Schaffert, Ph.D.	Member of the Executive Committee; President, Novartis Oncology	Member of the Executive Committee; President, Novartis Oncology	German
John Tsai, M.D.	Member of the Executive Committee; Global Head of Drug Development and Chief Medical Officer	Member of the Executive Committee; Head of Global Drug Development and Chief Medical Officer	American
Marie-France Tschudin	Member of the Executive Committee; President, Novartis Pharmaceuticals	Member of the Executive Committee; President, Novartis Pharmaceuticals	Swiss
Robert Weltevreden	Member of the Executive Committee; Head of Novartis Business Services	Member of the Executive Committee; Head of Novartis Business Services	Dutch

---

DIRECTORS AND EXECUTIVE OFFICERS OF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

The name, function, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis Institutes for BioMedical Research, Inc. (“NIBR”) are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite an individual’s name refers to employment with Novartis Institutes for BioMedical Research, Inc. and (ii) the business address of each director and executive officer for Novartis Institutes for BioMedical Research, Inc. is 250 Massachusetts Avenue, Cambridge, MA 02139, USA.

<b>Name</b>	<b>Relationship to Novartis Institutes for BioMedical Research, Inc.</b>	<b>Present Principal Occupation</b>	<b>Citizenship</b>
Joerg Reinhardt, Ph.D.	Chairman of the Board of Directors	Chairman of the Board of Directors, NIBR; Chairman of the Board of Directors; Novartis AG; Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland	German
Thomas Kendris	Director	President, Novartis Corporation; US Country President, Novartis Pharmaceuticals; Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland	American
Harry Kirsch	Director	Member of the Novartis AG Executive Committee; Chief Financial Officer, Novartis AG; Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland	German
James (Jay) Bradner, M.D.	Vice Chairman of the Board of Directors; President	Member of the Novartis AG Executive Committee; President of NIBR; Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland	American
Dimitris Agrafiotis	Chief Information Officer	Chief Information Officer, NIBR	American and Greek
Silvia Arber, Ph.D.	Senior Group Leader Musculoskeletal, FMI	Senior Group Leader Musculoskeletal, FMI, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland	Swiss

Evan Beckman, M.D.	Global Head Translational Medicine	Global Head Translational Medicine, NIBR	American
Tewis Bouwmeester, Ph.D.	Head DAX, CBT, NIBR Site Head Switzerland	Head DAX, CBT, NIBR Site Head Switzerland, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland	Netherlands
Karin Briner, Ph.D.	Head, Chemistry	Head, Chemistry, NIBR	Swiss
Scott Brown	Vice President and General Counsel; Chief Administrative Officer; Secretary	Vice President and General Counsel; Chief Administrative Officer; Secretary, NIBR	American
Christian Bruns, Ph.D.	Global Head, ATI	Global Head, ATI, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland	German
Fenella Chisholm	Global Head People & Organization	Global Head People & Organization, NIBR	British
Stephen Cho, Ph.D.	Global Head, Portfolio Management	Global Head, Portfolio Management, NIBR	American
Shaun Coughlin	Global Head CVM	Global Head CVM, NIBR	American
Thierry Diagana, Ph.D.	Head NITD	Head NITD, One Health Plaza, East Hannover, NJ 07936	American
Ricardo Dolmetsch, Ph.D.	Global Head, Neuroscience	Global Head, Neuroscience, NIBR	American, British, Colombian
Glenn Dranoff, M.D.	Global Head, Exploratory Immunology	Global Head, Exploratory Immunology, NIBR	American
Jeffrey Engelman, M.D., Ph.D.	Oncology Disease Area Head	Oncology Disease Area Head, NIBR	American

---

Mairead Goetz	Global Head, NIBR SciOps	Global Head, NIBR SciOps	Irish
Philip Gotwals, Ph.D.	Global Head BD&L	Global Head BD&L, NIBR	American
Cynthia Grosskreutz, M.D., Ph.D.	Global Head Ophthalmology Diseases	Global Head Ophthalmology Diseases, NIBR,	American
Jerry Joyce	Institute Director, GNF	Institute Director, GNF, Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121	American
Michaela Kneissel, Ph.D.	Global Head Musculoskeletal	Global Head Musculoskeletal, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland	Austrian
En Li, Ph.D.	Head CNIBR	Head CNIBR, Novartis Shanghai Campus, 4218 Kinke Road, Pudong New Area, Shanghai, China 201203	American
Jeffrey Lockwood	Head, NIBR Communications	Head, NIBR Communications, NIBR	American
Vishal Patel, Ph.D.	Chief of Staff	Chief of Staff, NIBR	American
Thomas Pietzonka, Dr. sc. nat	Global Head Biotherapeutic and Analytical Tech	Global Head Biotherapeutic and Analytical Tech, NIBR, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland	Swiss
Jeffrey Porter	Head Chemical Biology and Therapeutics	Head Chemical Biology and Therapeutics, NIBR	American
Revathi Rammohan	Chief Financial Officer and Head of Research Operations; Treasurer	Chief Financial Officer and Head of Research Operations; Treasurer, NIBR	British

---

Dirk Schuebeler, Ph.D.	Senior Group Leader, Musculoskeletal, FMI	Senior Group Leader, Musculoskeletal, FMI, Novartis Campus, Lichstrasse 35, CH-4056, Basel, Switzerland	German
Alice Shaw, M.D., Ph.D.	Global Head Translational Clinical Oncology	Global Head Translational Clinical Oncology, NIBR	American
Jean Silveri	Global Head R&D IP	Global Head R&D IP, NIBR	American
Fiona Spence, Ph.D.	Global Head of Preclinical Safety	Global Head of Preclinical Safety, NIBR	United Kingdom
Wendi Yajnik, Ph.D.	Global Head of Academic Partnerships and External Innovation	Global Head of Academic Partnerships and External Innovation, NIBR	American

---